求助PDF
{"title":"Evaluation of the antimicrobial prescribing pattern and the stewardship programs among COVID-19 hospitals in the capital city of Kurdistan-Northern Iraq: A multicenter point prevalence study","authors":"Belan Mustafa, A. Kurdi","doi":"10.24271/psr.2023.370659.1186","DOIUrl":null,"url":null,"abstract":"Antimicrobial resistance (AMR) is a significant threat to healthcare system as making infections difficult to be cured and enhances disease transmission and death. Thus, prudent antimicrobial use is crucial to combat AMR, particularly in Erbil City/Northern Iraq because of the high rate of multidrug-resistance microorganisms. There is limited data on the extent and quality of antimicrobial use in Kurdistan, including COVID-19 hospitals. This study aimed to assess the prevalence and quality indicators of antimicrobial use, the status of antimicrobial stewardship program (ASP), and hospital capacity infrastructures. From September 30th 2021 to February 8th 2022, all COVID-19 hospitals in Erbil/Northern Iraq were surveyed using the Global point prevalence survey methodology. Prevalence of antimicrobial use was at the top (100%, n = 71/71), and carbapenem was the most used antimicrobial class (44.0%, n = 55/125). The majority of the prescribed antimicrobials were in WHO Watch class (88.4%, n = 76/86), high use of parenteral therapy (99.2%, n = 124/125), low targeted therapy (2.4%, n = 3/125) and neither stop/review dates documented, nor local guidelines were available. ASP was not implemented while most of the hospitals had a priority for the medium or long term to implement ASP (66.7%, n = 2/3) out of 11 hospital capacity infrastructures, only four of them were present adequately. The findings demonstrated a high and sub-optimal quality of antimicrobial prescriptions, lack of ASP, and inadequate hospital capacity infrastructures. Quick action is necessary to establish ASP to combat antimicrobial resistance, and the critical target areas include development of the local guidelines and documenting stop/review date. © University of Garmian. All Rights Reserved.","PeriodicalId":33835,"journal":{"name":"Passer Journal","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Passer Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24271/psr.2023.370659.1186","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
引用
批量引用
库尔德斯坦-伊拉克北部首府城市COVID-19医院抗菌药物处方模式和管理方案评估:一项多中心点流行病学研究
抗微生物耐药性(AMR)是对医疗系统的重大威胁,因为它使感染难以治愈,并增加了疾病传播和死亡。因此,谨慎使用抗菌药物对于对抗AMR至关重要,特别是在伊拉克北部埃尔比勒市,因为多药耐药性微生物的比率很高。关于包括新冠肺炎医院在内的库尔德斯坦抗菌药物使用范围和质量的数据有限。本研究旨在评估抗菌药物使用的流行率和质量指标、抗菌药物管理计划(ASP)的现状以及医院能力基础设施。2021年9月30日至2022年2月8日,使用全球点流行率调查方法对伊拉克北部埃尔比勒的所有新冠肺炎医院进行了调查。抗菌药物使用率最高(100%,n=71/71),碳青霉烯类抗菌药物使用最多(44.0%,n=55/125)。大多数处方抗菌药物属于世界卫生组织观察类(88.4%,n=76/86)、高使用胃肠外治疗(99.2%,n=124/125)、低靶向治疗(2.4%,n=3/125),没有记录停药/复查日期,也没有当地指南。ASP没有实施,而在11个医院容量基础设施中,大多数医院都有实施ASP的中长期优先权(66.7%,n=2/3),其中只有4个足够。研究结果表明,抗菌药物处方质量高且次优,缺乏ASP,医院能力基础设施不足。建立ASP以对抗抗微生物耐药性是必要的,关键目标领域包括制定当地指南和记录停止/审查日期。©Garmian大学。保留所有权利。
本文章由计算机程序翻译,如有差异,请以英文原文为准。